Antibodies (Abs) are emerging as an important class of therapeutic agents for the treatment of various human diseases, often conjugated to drugs or toxic substances. In recent years, the incidence of cancer and infectious diseases has increased dramatically, making it imperative to discover new effective therapeutic molecules. Among these, small peptides are arousing great interest. Synthetic peptides, representative of variable and constant region fragments of Abs, were proved to exert in vitro, ex vivo and/or in vivo anti-microbial, anti-viral, anti-tumour and/or immunomodulatory activities, mediated by different mechanisms of action and regardless of the specificity and isotype of the Ab. Some of these synthetic peptides possess the ability to spontaneously and reversibly self-assemble in an organised network of fibril-like structure. Ab fragments may represent a novel model of targeted anti-infective and anti-tumour auto-delivering drugs.
DelvesP.J., and RoittI.M. (2000) The immune system. First of two parts. N. Engl. J. Med., 343, 37–49.
2.
TorresM., and CasadevallA. (2008) The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol., 29, 91–97.
3.
von BehringE., and KitasatoS. (1890) Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch. Med. Wochenschr., 16, 1113–1114.
4.
LindenmannJ. (1984) Origin of the terms ‘antibody’ and ‘antigen’. Scand. J. Immunol., 19, 281–285.
5.
MahendraA., SharmaM., RaoD.N., PeyronI., PlanchaisC., DimitrovJ.D., KaveriS.V., and Lacroix-DesmazesS. (2013) Antibody-mediated catalysis: induction and therapeutic relevance. Autoimmun. Rev., 12, 648–652.
6.
PolonelliL., ContiS., GerloniM., MaglianiW., CastagnolaM., MoraceG., and ChezziC. (1991) ‘Antibiobodies': antibiotic-like anti-idiotypic antibodies. J. Med. Vet. Mycol., 29, 235–242.
LiJ., and ZhuZ. (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol. Sin., 31, 1198–1207.
9.
BellouS., PentheroudakisG., MurphyC., and FotsisT. (2013) Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett., 338, 219–228.
10.
ShahP.S., and KaufmanD.A. (2009) Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst. Rev., CD006449.
11.
NagyE., GiefingC., and von GabainA. (2008) Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases. Expert Rev. Anti. Infect. Ther., 6, 21–30.
12.
DadachovaE., and CasadevallA. (2008) Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. Curr. Opin. Investig. Drugs, 9, 184–188.
13.
SassoonI., and BlancV. (2013) Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol. Biol., 1045, 1–27.
14.
LianosG.D., VlachosK., ZorasO., KatsiosC., ChoW.C., and RoukosD.H. (2014) Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco, Targets Ther, 7, 491–500.
NajjarV.A., and NishiokaK. (1970) “Tuftsin”: a natural phagocytosis stimulating peptide. Nature, 228, 672–673.
17.
VeretennikovaN.I., ChipensG.I., NikiforovichG.V., and BetinshY.R. (1981) Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis. Int. J. Pept. Protein Res., 17, 430–435.
18.
MorganE.L., HugliT.E., and WeigleW.O. (1982) Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1. Proc. Natl. Acad. Sci. USA, 79, 5388–5391.
19.
MitinY.V., NavolotskayaE.V., VasilenkoR.N., AbramovV.M., and Zav'YalovV.P. (1993) Synthesis and properties of the peptide corresponding to the ACTH-like sequence of human immunoglobulin G1. Int. J. Pept. Protein Res., 41, 517–521.
20.
Zav'yalovV.P., ZaitsevaO.R., NavolotskayaE.V., AbramovV.M., VolodinaE., and MitinY. V. (1996) Receptor-binding properties of the peptides corresponding to the beta-endorphin-like sequence of human immunoglobulin G. Immunol. Lett., 49, 21–26.
21.
JarrinA., AndrieuxA., ChapelA., BuchouT., and MarguerieG. (1994) A synthetic peptide with anti-platelet activity derived from a CDR of an anti-GPIIb-IIIa antibody. FEBS Lett., 354, 169–172.
22.
BourgeoisC., BourJ.B., AhoL.S., and PothierP. (1998) Prophylactic administration of a complementarity-determining region derived from a neutralising monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J. Virol., 72, 807–810.
23.
MonnetC., LauneD., Laroche-TraineauJ., Biard-PiechaczykM., BriantL., BesC., PugniereM., ManiJ.C., PauB., CeruttiM., DevauchelleG., DevauxC., GranierC., and ChardesT. (1999) Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J. Biol. Chem., 274, 3789–3796.
24.
ParkB.W., ZhangH.T., WuC., BerezovA., ZhangX., DuaR., WangQ., KaoG., O'RourkeD.M., GreeneM.I., and MuraliR. (2000) Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.Nat. Biotechnol., 18, 194–198.
25.
MoskalJ.R., KuoA.G., WeissC., WoodP.L., O'Connor HansonA., KelsoS., HarrisR.B., and DisterhoftJ.F. (2005) GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology, 49, 1077–1087.
26.
HeapC.J., WangY., PinheiroT.J., ReadingS.A., JenningsK.R., and DimmockN.J. (2005) Analysis of a 17-amino acid residue, virus-neutralising microantibody. J. Gen. Virol., 86, 1791–1800.
27.
DorfmanT., MooreM.J., GuthA.C., ChoeH., and FarzanM. (2006) A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralising antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem., 281, 28529–28535.
28.
QiuX.Q., WangH., CaiB., WangL.L., and YueS.T. (2007) Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumour targeting. Nat. Biotechnol., 25, 921–929.
29.
MozesE., SelaU., and SharabiA. (2008) A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action. Isr. Med. Assoc. J., 10, 40–42.
30.
OkarviS.M., and JammazI.A. (2009) Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumour-antigen- and antibody-derived peptides for the detection of breast cancer. Anticancer Res., 29, 1399–1409.
31.
JerneN.K. (1974) Towards a network theory of the immune system. Ann. Immunol. (Paris), 125C, 373–389.
32.
MaglianiW., ContiS., TravassosL.R., and PolonelliL. (2008) From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol. Lett., 288, 1–8.
33.
PolonelliL., MaglianiW., ContiS., BracciL., LozziL., NeriP., AdrianiD., De BernardisF., and CassoneA. (2003) Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun., 71, 6205–6212.
34.
ManfrediM., McCulloughM.J., ContiS., PolonelliL., VescoviP., Al-KaraawiZ.M., and PorterS.R. (2005) In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol. Immunol., 20, 226–232.
35.
CenciE., BistoniF., MencacciA., PeritoS., MaglianiW., ContiS., PolonelliL., and VecchiarelliA. (2004) A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol., 6, 953–961.
36.
TravassosL.R., SilvaL.S., RodriguesE.G., ContiS., SalatiA., MaglianiW., and PolonelliL. (2004) Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother., 54, 956–958.
37.
ContiS., MaglianiW., GiovatiL., LibriI., MaffeiD.L., SalatiA., and PolonelliL. (2008) Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiol., 31, 143–145.
38.
CafarchiaC., ImmediatoD., PaolaG.D., MaglianiW., CiociolaT., ContiS., OtrantoD., and PolonelliL. (2014) In vitro and in vivo activity of a killer peptide against Malassezia pachydermatis causing otitis in dogs. Med. Mycol., 52, 350–355.
39.
DoniniM., LicoC., BaschieriS., ContiS., MaglianiW., PolonelliL., and BenvenutoE. (2005) Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl. Environ. Microbiol., 71, 6360–6367.
40.
SavoiaD., ScuteraS., RaimondoS., ContiS., MaglianiW., and PolonelliL. (2006) Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Exp. Parasitol., 113, 186–192.
41.
FioriP.L., MattanaA., DessiD., ContiS., MaglianiW., and PolonelliL. (2006) In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J. Antimicrob. Chemother., 57, 891–898.
42.
CasoliC., PilottiE., PernoC.F., BalestraE., PolveriniE., CassoneA., ContiS., MaglianiW., and PolonelliL. (2006) A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. AIDS, 20, 975–980.
43.
ContiG., MaglianiW., ContiS., NencioniL., SgarbantiR., PalamaraA.T., and PolonelliL. (2008) Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob. Agents Chemother., 52, 4331–4337.
44.
OmaetxebarriaM.J., MoraguesM.D., ElguezabalN., Rodriguez-AlejandreA., BrenaS., SchneiderJ., PolonelliL., and PontonJ. (2005) Antifungal and antitumour activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans.Curr. Mol. Med., 5, 393–401.
PolonelliL., PontonJ., ElguezabalN., MoraguesM.D., CasoliC., PilottiE., RonziP., DobroffA.S., RodriguesE.G., JulianoM.A., MaffeiD.L., MaglianiW., ContiS., and TravassosL.R. (2008) Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumour activities. PLoS ONE, 3, e2371.
47.
PolonelliL., CiociolaT., MaglianiW., ZanelloP.P., D'AddaT., GalatiS., De BernardisF., AranciaS., GabrielliE., PericoliniE., VecchiarelliA., ArrudaD.C., PintoM.R., TravassosL.R., PertinhezT.A., SpisniA., and ContiS. (2012) Peptides of the constant region of antibodies display fungicidal activity. PLoS ONE, 7, e34105.
48.
ArrudaD.C., SantosL.C., MeloF.M., PereiraF.V., FigueiredoC.R., MatsuoA.L., MortaraR.A., JulianoM.A., RodriguesE.G., DobroffA.S., PolonelliL., and TravassosL.R. (2012) beta-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumour cells and is protective against metastatic melanoma. J. Biol. Chem., 287, 14912–14922.
49.
DobroffA.S., RodriguesE.G., JulianoM.A., FriacaD.M., NakayasuE.S., AlmeidaI.C., MortaraR.A., JacysynJ.F., Amarante-MendesG.P., MaglianiW., ContiS., PolonelliL., and TravassosL.R. (2010) Differential Antitumour Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Transl. Oncol., 3, 204–217.
50.
NavolotskayaE.V. (2014) The second life of antibodies. Biochemistry (Mosc.), 79, 1–7.
51.
CenciE., PericoliniE., MencacciA., ContiS., MaglianiW., BistoniF., PolonelliL., and VecchiarelliA. (2006) Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol., 79, 40–45.
52.
GabrielliE., PericoliniE., CenciE., OrtelliF., MaglianiW., CiociolaT., BistoniF., ContiS., VecchiarelliA., and PolonelliL. (2009) Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity. PLoS ONE, 4, e8187.
53.
GabrielliE., PericoliniE., CenciE., MonariC., MaglianiW., CiociolaT., ContiS., GattiR., BistoniF., PolonelliL., and VecchiarelliA. (2012) Antibody constant region peptides can display immunomodulatory activity through activation of the Dectin-1 signalling pathway. PLoS ONE, 7, e43972.
54.
PertinhezT.A., ContiS., FerrariE., MaglianiW., SpisniA., and PolonelliL. (2009) Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol. Pharm., 6, 1036–1039.
55.
MaglianiW., ContiS., CiociolaT., GiovatiL., ZanelloP.P., PertinhezT., SpisniA., and PolonelliL. (2011) Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs. Future Med. Chem., 3, 1209–1231.
56.
MaglianiW., ContiS., GiovatiL., ZanelloP.P., SperindeM., CiociolaT., and PolonelliL. (2012) Antibody Peptide based antifungal immunotherapy. Front. Microbiol., 3, 190.
CutuliM., CristianiS., LiptonJ.M., and CataniaA. (2000) Antimicrobial effects of alpha-MSH peptides. J. Leukoc. Biol., 67, 233–239.
59.
SforcaM.L., MachadoA., FigueredoR.C., OyamaS.Jr., SilvaF.D., MirandaA., DaffreS., MirandaM.T., SpisniA., and PertinhezT.A. (2005) The micelle-bound structure of an antimicrobial peptide derived from the alpha-chain of bovine hemoglobin isolated from the tick Boophilus microplus.Biochemistry (Mosc.), 44, 6440–6451.
60.
MaglianiW., ContiS., CunhaR.L., TravassosL.R., and PolonelliL. (2009) Antibodies as crypts of antiinfective and antitumour peptides. Curr. Med. Chem., 16, 2305–2323.
